DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, has signed an agreement with Tunitas Therapeutics to provide process development activities for Tunitas' lead Fc-fusion protein for the treatment of asthma and other allergic diseases.
DSM will manufacture drug product from its Groningen facility in The Netherlands and later at its Brisbane, Australia, facility. Tunitas recently established a subsidiary Tunitas Therapeutics Australia Pty Ltd. in Melbourne, Australia.
"We are delighted to be working with DSM Biologics for the production of Tunitas' first clinical candidate." said Nolan Sigal, president and chief executive officer of Tunitas Therapeutics. "DSM has an outstanding and well-earned reputation for the production of biologics of the highest quality. Furthermore, the opening of the DSM's state-of-the-art facility in Brisbane, Australia fits nicely with our strategy to begin development activities in Australia."
Manja Bouman, president of DSM Biologics, said, “It is an honor to support the development of Tunitas' promising drug candidate from our facilities in Groningen and Australia. We are impressed with the potential of this product and the health benefit to treat the millions of patients whose asthma is poorly-controlled on their current therapeutic regimens."